SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotransplant(BTRN)
BTRN 35.410.0%Nov 26 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Micawber who wrote (966)7/28/2001 11:28:40 AM
From: Arthur Radley   of 1475
 
Brian, I had seen the article and fully agree that much works is in store for companies to develop this into a viable treatment method. It is MO that Bush will have to move on this issue and give his approval in the near future.

With reference to this NY Times article, the part that I like and IMO will be a plus for BTRN is ...."as with blood transfusions or organ transplants, cells can carry infections or be rejected by th patient's immune system." Not only does BTRN have projects dealing with the rejection issue, but with the recent purchase of Eligix, they address the purification issue of potential infected cells. And then with the Austrilian company, they have a toe in the door with the actual stem cell research. Plus, the safe net with the Medimune drug that is moving through the clinicals. From my perspective, BTRN has every aspect covered, if stem cell research is expanded and if something viable comes from this area of medical treatment.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News